by Swiss Approval | 26 July 2024 | Lung Cancer
Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...
by Ilaria Colombo | 19 July 2024 | Women's Cancers
Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
by PEAK Medicals | 17 July 2024 | OncoNews
We are thrilled to announce our new partnership with Universimed, a renowned medical publisher, and their esteemed journal, Leading Opinions. This collaboration marks a significant step forward in our commitment to advancing oncology education.  © OncoViews As part of...
by EMA Approval | 12 July 2024 | Urogenital, Women's Cancers
The European Union has recommended new treatment options for patients with primary advanced or recurrent endometrial cancer and metastatic urothelial carcinoma. Durvalumab and Olaparib have been endorsed for endometrial cancer based on positive trial results, while...
by Swiss Approval | 4 July 2024 | Lung Cancer
Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, has received approval from Swissmedic for the treatment of adult patients with resectable NSCLC (tumours ≥4 cm and/or positive...